Last updated: September 9, 2026
The hydrocodone bitartrate/pseudoephedrine hydrochloride market is a small, mature U.S. prescription cough-and-cold segment with declining commercial potential. Demand is constrained by hydrocodone’s Schedule II status, opioid-prescribing controls, abuse-deterrence concerns, pseudoephedrine purchase restrictions, and competition from non-opioid cough products. Product-level revenue is generally not disclosed because the combination is sold through private-label, generic, and small branded portfolios rather than a large standalone franchise.
The commercial outlook is weak to stable at best. Revenue depends more on distribution access, DEA-compliant supply, state prescribing rules, and payer coverage than on clinical differentiation or patent exclusivity.
What is hydrocodone bitartrate and pseudoephedrine hydrochloride used for?
Hydrocodone bitartrate is an opioid antitussive. Pseudoephedrine hydrochloride is a nasal decongestant. Combination products are prescribed for cough and upper-respiratory symptoms associated with congestion.
Typical oral solutions contain approximately 5 mg of hydrocodone bitartrate and 30 mg of pseudoephedrine hydrochloride per 5 mL, although strengths and labeling can vary by product. The combination is administered orally and is generally marketed as a prescription-only cough-and-cold medicine.
The product category competes with:
- Dextromethorphan-based cough suppressants
- Benzonatate
- Codeine-containing cough products
- Hydrocodone/homatropine products
- Antihistamine/decongestant combinations
- Intranasal decongestants
- Nonprescription expectorants and cough syrups
Hydrocodone provides cough suppression but creates a substantially higher regulatory burden than non-opioid alternatives.
What is the FDA regulatory status of hydrocodone-pseudoephedrine products?
Hydrocodone is a Schedule II controlled substance in the United States. Schedule II status imposes strict prescribing, dispensing, recordkeeping, inventory, and refill requirements. A Schedule II prescription generally cannot be refilled under federal law, although a practitioner may issue multiple prescriptions subject to applicable rules.[1]
Pseudoephedrine is regulated under the Combat Methamphetamine Epidemic Act. Retail sales are subject to daily and monthly purchase limits, identification requirements, transaction records, and behind-the-counter or locked-storage controls.[2]
This combination therefore carries two separate compliance burdens:
| Component |
Regulatory issue |
Commercial effect |
| Hydrocodone bitartrate |
Schedule II opioid |
Limits refills, increases pharmacy controls, raises diversion risk |
| Pseudoephedrine HCl |
Precursor-chemical restrictions |
Limits retail access and inventory flexibility |
| Combination product |
Prescription cough-and-cold indication |
Narrows prescriber and pharmacy channels |
FDA safety communications have also affected opioid prescribing behavior. The agency has emphasized risks of misuse, addiction, overdose, respiratory depression, and accidental exposure for opioid-containing medicines.[3]
When does hydrocodone-pseudoephedrine lose exclusivity?
The combination does not have one universal exclusivity date because exclusivity depends on the specific NDA, formulation, sponsor, and approval history.
For mature hydrocodone-pseudoephedrine products, the main commercial issue is usually not pending regulatory exclusivity. The category is generally exposed to generic and therapeutically substitutable competition. FDA’s Orange Book identifies patents and regulatory exclusivity by approved application, not by active ingredient pair alone.[4]
The relevant exclusivity categories are:
| Exclusivity type |
Relevance to this combination |
| New chemical entity exclusivity |
Generally not applicable because hydrocodone and pseudoephedrine are established ingredients |
| New clinical investigation exclusivity |
Possible only if FDA granted qualifying exclusivity for a specific approval |
| Orphan-drug exclusivity |
Not relevant to an ordinary cough-and-cold indication |
| Pediatric exclusivity |
Could extend listed protections by six months if granted |
| Patent protection |
Depends on the specific formulation, manufacturing process, or method-of-use patent |
| Regulatory exclusivity for a reformulation |
Possible, but limited to the qualifying product and approved claims |
A company evaluating a particular product must review its NDA number, Orange Book listings, FDA approval history, and patent certifications. The ingredient description alone does not identify a complete patent position.
What patents protect hydrocodone bitartrate and pseudoephedrine hydrochloride?
The active ingredients themselves are old and do not normally support meaningful composition-of-matter exclusivity for current products. Potential protection is more likely to arise from:
- Extended-release or modified-release delivery
- Taste-masked oral solutions
- Abuse-deterrent formulations
- Stabilized liquid formulations
- Specific concentration ranges
- Manufacturing and purification processes
- Container-closure systems
- Methods for treating cough with a defined patient population
- Combination formulations containing an additional antihistamine or expectorant
For a conventional immediate-release oral solution, formulation patents may be less commercially durable than patents covering abuse-deterrent or modified-release opioid products. Generic applicants can often design around narrow formulation claims if the reference product has no clinically important delivery-system advantage.
What is the Orange Book status of hydrocodone-pseudoephedrine products?
Orange Book status must be assessed at the individual application level. A product may be:
- Listed as an approved prescription drug without current patent protection
- Associated with expired patents
- Associated with patents that do not block all generic formulations
- Discontinued commercially but retained in FDA records
- Referenced by an ANDA even when the original brand has limited sales
FDA’s Orange Book does not establish whether a product has meaningful market demand. It identifies approved products, therapeutic equivalence, patents submitted by NDA sponsors, and applicable exclusivity information.[4]
The financial risk is highest when an ANDA applicant can file a Paragraph IV certification against a listed patent. The litigation period can delay approval, but the delay does not create durable value if the underlying market is contracting.
How many patents cover hydrocodone-pseudoephedrine products?
There is no reliable single patent count for the ingredient pair. Patent coverage depends on the specific product and NDA.
A conventional oral solution may have limited active protection, while a branded product with abuse-deterrent technology, a specialized delivery device, or a novel release profile may have a larger patent family. Patent counts should distinguish:
- Granted U.S. patents
- Pending U.S. applications
- Orange Book-listed patents
- Expired patents
- Continuations and divisionals
- International family members
- Patents that materially block an ANDA
Patent-family volume alone is a weak measure of commercial strength. The most important question is whether an unexpired, enforceable claim covers the proposed generic’s formulation or method of use.
Are Paragraph IV challenges likely for hydrocodone-pseudoephedrine?
Paragraph IV risk is structurally moderate but commercially limited. A generic applicant can challenge an Orange Book-listed patent by asserting that the patent is invalid, unenforceable, or not infringed. The NDA holder may then file suit within 45 days, potentially triggering a 30-month stay of ANDA approval under the Hatch-Waxman framework.[5]
For a mature combination product, the likely outcomes are:
- No challenge because listed patents are expired or commercially irrelevant
- A Paragraph IV filing against a narrow formulation patent
- Early settlement allowing a licensed generic launch
- Litigation followed by approval after patent expiry or successful invalidity findings
- Multiple generic approvals with limited value per entrant
The commercial prize is small if prescription volume has already shifted away from opioid cough products. Patent litigation costs can exceed the expected value of the product unless the challenger has a broader respiratory portfolio or an established controlled-substance distribution network.
What generic entry risks exist?
Generic entry risk is high where the reference product has:
- Immediate-release liquid dosage form
- No abuse-deterrent technology
- No clinically differentiated delivery system
- Expired or absent Orange Book patents
- Established pharmaceutical equivalence criteria
- Low switching costs for pharmacies and wholesalers
Generic substitution can be less automatic for controlled-substance liquids than for ordinary tablets because pharmacies manage supply reliability, state rules, wholesaler allocation, and diversion controls. That friction can preserve modest brand or authorized-generic economics, but it does not create strong pricing power.
The main generic-entry scenarios are:
| Scenario |
Likely market result |
| One approved generic |
Moderate price pressure; incumbent may retain distribution accounts |
| Multiple generic entrants |
Rapid price erosion and lower gross margins |
| Authorized generic launch |
Faster erosion of independent generic economics |
| Supply shortage |
Temporary price and share volatility |
| Brand withdrawal |
Market may migrate to other hydrocodone or non-opioid products |
Which companies are challenging or competing with the product?
Competition is fragmented. Relevant competitors include manufacturers of:
- Generic hydrocodone/pseudoephedrine oral solutions
- Hydrocodone/homatropine products
- Hydrocodone-containing cough combinations
- Dextromethorphan products
- Benzonatate
- Codeine cough products
- Antihistamine/decongestant liquids
- Nonprescription cough and cold products
Large generic manufacturers may participate through abbreviated new drug applications, contract manufacturing, or private-label supply. Smaller specialty pharmaceutical companies may commercialize the product through focused respiratory or controlled-substance portfolios.
The competitive advantage is operational rather than scientific. The strongest suppliers are likely to have:
- DEA-compliant manufacturing and distribution
- Reliable active pharmaceutical ingredient supply
- State-compliant controlled-substance operations
- National wholesaler access
- Liquid-dose manufacturing capacity
- Low-cost packaging and serialization systems
- Pharmacy and institutional account relationships
How does this market compare with other opioid cough medicines?
Hydrocodone-pseudoephedrine has a more complicated commercial profile than hydrocodone/homatropine because pseudoephedrine introduces precursor-chemical controls. It can offer decongestant utility, but that benefit is increasingly available through separate non-opioid products.
| Product category |
Opioid burden |
Decongestant burden |
Market outlook |
| Hydrocodone/pseudoephedrine |
High |
High |
Small and declining |
| Hydrocodone/homatropine |
High |
Low |
Mature, constrained |
| Codeine cough products |
High |
Variable |
Declining in many channels |
| Dextromethorphan |
None under federal controlled-substance rules |
Variable |
Larger consumer market |
| Benzonatate |
None |
None |
Prescription alternative with broader access |
The combination’s therapeutic logic is clear, but the commercial case is weaker than for non-opioid cough suppressants because prescribers and pharmacies face greater compliance exposure.
What is the financial trajectory of hydrocodone-pseudoephedrine?
Public companies generally do not report revenue for this ingredient pair separately. Financial analysis must therefore rely on market structure rather than product-level sales disclosures.
Revenue trajectory
The expected trajectory is:
- Historical revenue supported by prescription cough demand and branded formulations.
- Gradual decline from genericization and reduced opioid prescribing.
- Margin compression as additional suppliers enter.
- Episodic volatility from controlled-substance shortages and allocation limits.
- Further substitution toward non-opioid cough medicines.
The market may still generate attractive cash flow for a low-cost manufacturer with an approved product and stable supply. It is unlikely to support major research investment, premium licensing payments, or a high-value standalone acquisition unless the asset includes differentiated formulation technology.
Key financial drivers
| Driver |
Direction |
Impact |
| Opioid prescribing controls |
Negative |
Reduces eligible prescriptions |
| Generic competition |
Negative |
Compresses price and gross margin |
| Pseudoephedrine restrictions |
Negative |
Reduces retail convenience |
| Manufacturing shortages |
Mixed |
Can temporarily support share or pricing |
| Non-opioid substitution |
Negative |
Shrinks addressable demand |
| Specialty distribution |
Positive for incumbents |
Supports retention of controlled-substance accounts |
| Reformulation or abuse deterrence |
Potentially positive |
Could support differentiation if clinically and commercially accepted |
What manufacturing and intellectual-property barriers matter most?
Manufacturing barriers are more important than basic active-ingredient patents. Hydrocodone and pseudoephedrine require controlled-substance and precursor-chemical compliance, respectively. A manufacturer must manage:
- DEA registration and quotas
- Secure storage and inventory reconciliation
- Diversion monitoring
- Batch traceability
- Liquid-content uniformity
- Stability and preservative controls
- Child-resistant packaging
- Serialization and supply-chain reporting
- State-level controlled-substance requirements
A generic manufacturer with an approved liquid product may have a practical advantage over a patent holder without reliable manufacturing capacity. Conversely, a patent portfolio without supply reliability provides limited commercial protection.
What licensing deals and settlement agreements affect the market?
No major publicly visible licensing economics are associated with the ingredient pair as a standalone category. Licensing is more likely to occur through:
- Authorized-generic arrangements
- Contract manufacturing agreements
- Portfolio acquisitions involving several cough-and-cold products
- Distribution licenses for branded oral solutions
- Settlements tied to a specific formulation patent
Settlement value depends on remaining patent life, expected generic launch date, market size, and the number of potential entrants. In a low-volume market, an early-entry settlement may have limited financial significance compared with a blockbuster drug settlement.
What generic launch scenarios should investors model?
Investors should model three cases:
Base case
The product remains available through a small number of manufacturers. Volume declines gradually, prices remain under pressure, and revenue becomes dependent on supply continuity and account retention.
Downside case
Multiple ANDA holders enter, pharmacies substitute aggressively, and the product loses formulary and wholesaler relevance. Revenue falls rapidly, with controlled-substance compliance costs limiting margin recovery.
Upside case
A shortage among competitors or a manufacturing withdrawal temporarily increases demand. An incumbent captures share, but the benefit is likely episodic because additional generic supply can return quickly.
The upside case does not depend on strong patent exclusivity. It depends on supply disruption, manufacturing reliability, and channel execution.
What is the geographic coverage of the market?
The commercial opportunity is concentrated in the United States because pseudoephedrine controls and hydrocodone scheduling are U.S.-specific regulatory issues. International markets use different opioid classifications, decongestant rules, product approvals, and prescribing practices.
A U.S. product cannot be assumed to have transferable international value. Export potential requires separate review of:
- National marketing authorization
- Controlled-substance import and export rules
- Local opioid scheduling
- Pseudoephedrine restrictions
- Product labeling
- Pharmacovigilance requirements
- Local manufacturing and distribution licenses
Key Takeaways
- Hydrocodone bitartrate/pseudoephedrine hydrochloride is a mature, niche prescription cough-and-cold market.
- Hydrocodone Schedule II controls and pseudoephedrine restrictions create substantial operating friction.
- The active ingredients do not generally provide a strong modern composition-of-matter patent position.
- Commercial protection depends on product-specific formulation patents, manufacturing capability, distribution, and regulatory compliance.
- Paragraph IV risk is possible but often has limited economic value because the underlying market is small and declining.
- Product-level revenue is not normally disclosed by public companies.
- The likely financial trajectory is declining volume, lower pricing, and episodic supply-driven volatility.
- Non-opioid cough treatments are the principal competitive threat.
- The most valuable assets are approved supply, reliable DEA-compliant manufacturing, and channel access rather than broad patent portfolios.
FAQs
Is hydrocodone bitartrate and pseudoephedrine hydrochloride the same as hydrocodone-homatropine?
No. Hydrocodone-homatropine contains hydrocodone and homatropine, while hydrocodone-pseudoephedrine contains hydrocodone and pseudoephedrine. The products have different formulations, labeling, regulatory considerations, and Orange Book records.
Can hydrocodone-pseudoephedrine be sold over the counter?
No. Hydrocodone-containing medicines require a prescription. Pseudoephedrine is also subject to federal retail-sale controls.
Does pseudoephedrine create a separate patent barrier?
Usually not. Pseudoephedrine is an established active ingredient. Its principal commercial effect is regulatory control over sales, inventory, and transactions rather than patent exclusivity.
Is a hydrocodone-pseudoephedrine liquid difficult to manufacture?
It can be operationally demanding because the manufacturer must meet controlled-substance security requirements, pseudoephedrine controls, liquid-dose uniformity standards, stability requirements, and packaging rules.
Does FDA approval guarantee commercial substitution?
No. FDA approval establishes regulatory eligibility. Pharmacy substitution, wholesaler access, payer coverage, state requirements, supply reliability, and controlled-substance availability determine actual commercial uptake.
References
- U.S. Drug Enforcement Administration. (2024). Drug scheduling. https://www.dea.gov/drug-information/drug-scheduling
- U.S. Food and Drug Administration. (2024). Combat methamphetamine epidemic act. https://www.fda.gov/drugs/information-drug-class/combat-methamphetamine-epidemic-act
- U.S. Food and Drug Administration. (2024). Opioid medications. https://www.fda.gov/drugs/information-drug-class/opioid-medications
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
- U.S. Code. (2024). 21 U.S.C. § 355: New drugs. https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section355&num=0&edition=prelim
